Results 1 to 10 of about 362,523 (334)

Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]

, 2013
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Bermudez, Olga, Eickelberg, Oliver, Hennen, Elisabeth, Koch, Ina, Lindner, Michael   +4 more
core   +22 more sources

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan

Asian Pacific Journal of Cancer Biology, 2021
Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) are EGFR-tyrosine kinase inhibitors (TKIs).
Jae Cheol Lee, Jen-Yu Hung, Young-Chul Kim, Gee-Chen Chang, Seung Soo Yoo, Sheng-Hsiung Yang, Keith L Davis, Saurabh P Nagar, Aliki Taylor, Sung Yong Lee, Jin-Yuan Shih   +10 more
doaj   +1 more source

Laminin-bound integrin α6β4 promotes non-small cell lung cancer progression via the activation of YAP/TAZ signaling pathway

Frontiers in Oncology, 2022
Laminin is an extracellular matrix multidomain trimeric glycoprotein, that has a potential role in tumor progression. Here, we studied the effects of non-small cell lung cancer (NSCLC) cells interaction on laminin and explored the underlying mechanism of
Xiaopeng Zhao, Chuang Liu, Xu He, Miao Wang, Haoran Zhang, Jingge Cheng, Hongyan Wang   +6 more
doaj   +1 more source

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study

Фармакоэкономика, 2023
Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Materials and methods. The calculations
A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina   +3 more
doaj   +1 more source

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

Сибирский онкологический журнал, 2023
Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods ...
D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, T. D. Barbolina, I. A. Djanyan   +4 more
doaj   +1 more source

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

Исследования и практика в медицине, 2021
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov   +5 more
doaj   +1 more source

Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway

Cancer Cell International, 2020
Background Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effective in treating advanced lung cancer patients through prolonging the drug resistance to Gefitinib (GFTN).
Sumei Wang, Zhiwei Peng, Wenjuan Li, Shunqin Long, Shujing Xiao, Wanyin Wu   +5 more
doaj   +1 more source

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping

Медицинский совет, 2021
Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities ...
M. O. Mandrina, V. V. Breder, M. V. Ivanov, A. A. Lebedeva, V. V. Gorbatsevich, K. K. Laktionov, P. V. Kononets   +6 more
doaj   +1 more source

Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series

Cancer Research, Statistics, and Treatment, 2021
Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones.
Sandip Ganguly, Joydeep Ghosh, Anisha Gehani, Archisman Basu, Meheli Chatterjee, Deepak Dabkara, Bivas Biswas   +6 more
doaj   +1 more source

Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma

Pharmaceutical Biology, 2020
Context Aaptamine is a potent ocean-derived non-traditional drug candidate against human cancers. However, the underlying molecular mechanisms governing aaptamine-mediated repression of lung cancer cells remain largely undefined. Objective To examine the
Kaikai Gong, Shuang Miao, Lijuan Yang, Yan Wu, Jiwei Guo, Weiwei Chen, Juanjuan Dai, Jing Du, Sichuan Xi   +8 more
doaj   +1 more source